⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315905 | 1.00 | — | — | |
| SCHEMBL25316899 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29539199 | 0.96 | L3MBTL1 (0.55) | — | |
| SCHEMBL16878818 | 0.84 | L3MBTL1 (0.46) | — | |
| SCHEMBL16878061 | 0.84 | — | — | |
| SCHEMBL30360177 | 0.84 | — | — | |
| SCHEMBL939664 | 0.84 | L3MBTL1 (0.46) | — | |
| SCHEMBL214038 | 0.84 | L3MBTL1 (0.46) | — | |
| SCHEMBL22389997 | 0.84 | L3MBTL1 (0.46) | — | |
| SCHEMBL3814583 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | claimed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | claimed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4308097-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | The Regents Of The University Of Michigan (US) | 2024-01-24 | — | — | EP | claimed |
| WO-2022197690-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-22 | — | — | WO | claimed |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | claimed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | claimed |
| EP-3189061-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | claimed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | claimed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250368646-A1 | TRICYCLIC FUSED WRN INHIBITORS | NIMBUS WADJET INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12459931-B2 | Benzothiophene derivative regulator, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-04 | — | — | US | disclosed |
| US-12421233-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |